Core Viewpoint - The company's short-term performance is under pressure due to multiple factors, but overall revenue is expected to stabilize in the second half of 2025, with a potential narrowing of profit decline [1][4] Financial Performance - In the first half of 2025, the company reported revenue of 1.289 billion yuan, a year-on-year decrease of 10.7%, and a net loss attributable to shareholders of 1.044 billion yuan, compared to a net profit of 190 million yuan in the same period last year [1][2] - Adjusted net profit was 82 million yuan, down 68.3% year-on-year, with earnings per share (EPS) at -0.39 yuan [1][2] Regional Performance - Chengdu's medical service revenue was approximately 768 million yuan, with the number of egg retrieval cycles decreasing by 6.1% to 7,111 due to an increase in IUI cycle patients [2] - The Greater Bay Area generated 206 million yuan in medical service revenue, with egg retrieval cycles down 16.0% to 2,539, influenced by changes in clinical procedures [2] - Revenue from Kunming and Wuhan was 131 million yuan, with egg retrieval cycles down 3.5% to 2,059, mainly due to hospital renovations [2] - Overseas medical service revenue was 405 million yuan, with egg retrieval cycles down 8.9% to 2,058, but revenue remained stable year-on-year [2] Market and Policy Environment - Since 2021, a series of policies encouraging childbirth have been introduced in China, with all 31 provinces and regions including assisted reproduction in medical insurance by March 2025, expected to enhance technology penetration [3] - The delay of California's commercial insurance law until January 2026 is anticipated to drive growth in treatment cycles in the U.S. market over the next 3-5 years [3] Profitability and Cost Management - The company's overall gross margin for the first half of 2025 was 30.4%, a decrease of 10 percentage points year-on-year, primarily due to the increased proportion of lower-margin IUI cycles and price pressures from medical insurance [3] - Sales and distribution expenses decreased by 14.5% to 74 million yuan, while R&D expenses fell by 17.4% to 9 million yuan [3] Future Outlook - The company is expected to benefit from the gradual release of domestic fertility support policy dividends and the continuous improvement of assisted reproduction penetration rates [5] - Revenue projections for 2025-2027 are 2.650 billion, 2.875 billion, and 3.132 billion yuan, with year-on-year growth rates of -5.76%, 8.52%, and 8.91% respectively [5]